Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
30 p, 7.5 MB The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer / De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Sammut, S.J. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Ross, E.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Bashford-Rogers, R. (Department of Medicine. University of Cambridge) ; Greenstein, E. (Weizmann Institute of Science (Israel). Department of Immunology) ; Markus, H. (Mayo Clinic Center for Individualized Medicine) ; Morganella, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Teng, Y. (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ; Maruvka, Y. (Massachusetts General Hospital) ; Pereira, B. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Rueda, O.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Chin, S.F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Contente-Cuomo, T. (Mayo Clinic Center for Individualized Medicine) ; Mayor, R. (Centro de Investigación Biomédica en Red de Cáncer) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Ali, H.R. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Cope, W. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Tiezzi, D. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Dariush, A. (Institute of Astronomy. University of Cambridge) ; Dias Amarante, T. (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Reshef, D. (Weizmann Institute of Science (Israel). Department of Immunology) ; Ciriaco, 0000-0002-1151-554X (Hospital Universitari Vall d'Hebron) ; Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ; Vassiliou, G. (Wellcome Trust/MRC Cambridge Stem Cell Institute) ; Getz, G. (Massachusetts General Hospital) ; Nik-Zainal, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Murtaza, M. (Mayo Clinic Center for Individualized Medicine) ; Friedman, N. (Weizmann Institute of Science (Israel). Department of Immunology) ; Markowetz, F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Caldas, C. (Cancer Research UK Cambridge Cancer Centre (Regne Unit)) ; Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 - 10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10  
2.
8 p, 473.7 KB RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer / Cruz, C. (Vall d'Hebron Institut d'Oncologia) ; Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ; Gutiérrez-Enríquez, S. (Oncogenetics Group) ; Llop-Guevara, A. (Experimental Therapeutics Group) ; Ibrahim, Y.H. (Experimental Therapeutics Group) ; Gris-Oliver, Albert. (Experimental Therapeutics Group) ; Bonache, S. (Oncogenetics Group) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Bruna, A. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Lai, Z. (AstraZeneca (USA)) ; Polanska, U.M. (Cancer Research UK. Cambridge Institute) ; Jones, G.N. (Cancer Research UK. Cambridge Institute) ; Kristel, P. (The Netherlands Cancer Institute (NKI) (Netherlands)) ; de Bustos, L. (Experimental Therapeutics Group) ; Guzman, M. (Experimental Therapeutics Group) ; Rodríguez, O. (Experimental Therapeutics Group) ; Grueso, J. (Experimental Therapeutics Group) ; Montalban, G. (Oncogenetics Group) ; Caratú, G. (Cancer Genomics Group) ; Mancuso, F. (Cancer Genomics Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ; Howat, W.J. (Cancer Research UK. Cambridge Institute) ; Dougherty, B. (AstraZeneca (USA)) ; Vivancos, A. (Cancer Genomics Group) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Serres-Créixams, X. (Department of Radiology) ; Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ; Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ; Cadogan, E. (Cancer Research UK. Cambridge Institute) ; Barrett, J.C. (AstraZeneca (USA)) ; Caldas, C. (NIHR Cambridge Biomedical Research Centre (Regne Unit)) ; Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Jonkers, J. (Cancer Genomics Group) ; Diez, Orland (Hospital Universitari Vall d'Hebron) ; O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210  

Vea también: autores con nombres similares
1 Rueda, Oscar M.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.